BioCentury
ARTICLE | Clinical News

MGI Pharma ovarian cancer data

April 6, 2000 7:00 AM UTC

MOGN said preliminary PhaseII results for its Irofulven hydroxymethylacylfulvene ( MGI 114) showed efficacy in 15 patients with ovarian cancer who had failed other therapies. Five patients showed a pa...